Conventional human pluripotent stem cells at the primed pluripotent state are capable of generating all the embryonic lineages. However, their ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...